Motexafin gadolinium: A clinical review of a novel radioenhancer for brain tumors

Expert Review of Anticancer Therapy

Volumn 4, Issue 6, 2004, Pages 981-989

  Khuntia, Deepak ^a   Mehta, Minesh ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Brain metastasis; Motexafin gadolinium; Radiation sensitizers

Indexed keywords

BORON 10; BROXURIDINE; CISPLATIN; DNA; DOCETAXEL; DOXORUBICIN; EFAPROXIRAL; GADOLINIUM; GADOLINIUM TEXAPHYRIN; LOMUSTINE; MISONIDAZOLE; OXYGEN; PROCARBAZINE; RADIOSENSITIZING AGENT; TEMOZOLOMIDE; TIRAPAZAMINE; VINCRISTINE; YTTRIUM 90;

ACUTE KIDNEY TUBULE NECROSIS; ALLERGIC REACTION; BRAIN METASTASIS; BRAIN TUMOR; BULLOUS SKIN DISEASE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXEMIA; INJECTION SITE; INJECTION SITE REACTION; LIVER TOXICITY; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; NAUSEA; NEUTRON CAPTURE THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRURITUS; RADIATION BEAM; REVIEW; SCLERA DISEASE; SIDE EFFECT; TACHYCARDIA; URINE COLOR;

EID: 10644246037     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.6.981     Document Type: Review

References (35)

1. Datta R, Jawahar A, Ampil FL, Shi R, Nanda A, D'Agostino H. Survival in relation to radiotherapeutic modality for brain metastasis: whole brain irradiation vs. gamma knife radiosurgery. Am. J. Clin. Oncol. 27(4), 420-424 (2004).
2. Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37(4), 745-751 (1997).
3. Epstein BE, Scott CB, Sause WT et al. Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28. Cancer 71(4), 1362-1367 (1993).
4. Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17), 1485-1489 (1998).
5. Hall E. Radiobiology for the Radiobiologist, fifth edition Lippincott Williams & Wilkins, PA, USA, 446-460 (2000).
6. Churchill-Davidson I. Hyperbaric oxygen and radiotherapy: general principles and problems. Nunt Radiol. 34(1), 5-13 (1968).
7. Suh J, Stea B, Nabid A et al. Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O2), with or without RSR13 (efaproxiral) in patients with brain metastases: results of the randomized REACH (RT-009) study. J. Clin. Oncol. 22(Suppl 14), 115s (2004) (Abstract 1534).
8. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin. Radiat. Oncol. 13(1), 13-21 (2003).
9. Carde P, Timmerman R, Mehta MP et al. Multicenter Phase IB/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J. Clin. Oncol. 19(7), 2074-2083 (2001).
10. Mehta MP, Shapiro WR, Glantz MJ et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J. Clin. Oncol. 20(16), 3445-3453 (2002).
11. Mehta MP, Rodrigus P, Terhaard CH et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 21(13), 2529-2536 (2003).
12. Viala J, Vanel D, Meingan P, Lartigau E, Carde P, Renschler M. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology 212(3), 755-759 (1999).
13. American Cancer Society. Statistics for 2004. American Cancer Society (2004).
14. Del Rowe J, Scott C, Werner-Wasik M et al. Single-arm, open-label Phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol. 18(6), 1254-1259 (2000).
15. Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl Cancer Inst. 85(9 , 704-710 (1993).
16. Prados MD, Scott C, Sandler H et al. A Phase III randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. Int. J. Radiat. Oncol. Biol. Phys. 45(5), 1109-1115 (1999).
17. Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R. A randomized Phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int. J. Radiat. Oncol. Biol. Phys. 20(1), 53-58 (1991).
18. Shaw E, Scott C, Suh J et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J. Clin. Oncol. 21(12), 2364-2371 (2003).
19. Kleinberg L, Grossman SA, Carson K et al. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a Phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J. Clin. Oncol. 20(14), 3149-3155 (2002).
20. Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem. Pharmacol. 59(7), 733-739 (2000).
21. Rowinsky EK. Novel radiation sensitizers targeting tissue hypoxia. Oncology (Huntingt) 13(10 Suppl. 5), 61-70 (1999).
22. Rodrigus P. Motexafin gadolinium: a possible new radiosensitiser. Expert Opin. Investig. Drugs 12(7), 1205-1210 (2003).
23. Donnelly ET, Liu Y, Fatunmbi YO, Lee I, Magda D, Rockwell S. Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. Int. J. Radiat. Oncol. Biol. Phys. 58(5), 1570-1576 (2004).
24. Young SW, Sidhu MK, Qing F et al. Preclinical evaluation of gadolinium. (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging. Invest. Radiol. 29(3), 330-338 (1994).
25. Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int. J. Radial. Oncol. Biol. Phys. 45(4), 981-989 (1999).
26. Ford JM. A Phase I dose escalation trial of motexafin gadolinium as a radiation sensitizer in patients with newly diagnosed glioblastoma multiforme. Proc. Am. Soc. Ther. Radiol. Oncol. (2001) (Abstract 1059).
27. Young SW, Qing F, Harriman A et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl Acad. Sci. USA 93(13), 6610-6615 (1996).
28. Kesslering C. Selective uptake and retention of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) in tumors demonstrated by MRI in Phase I and Phase II clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 42, 263 (1998).
29. Naumovski L, Chen J, Ramos J et al. Inhibition of growth and induction of apoptosis by motexafin gadolinium (Xcytrin®) alone and in combination with other therapeutic agents in lymphoma and myeloma tumor cell lines. Blood 102, 213b (2003) (Abstract 4573).
30. Meyers CA, Smith JA, Bezjak A et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized Phase III trial. J. Clin. Oncol. 22(1), 157-165 (2004).
31. Suh J, Chang E, Timmerman R et al. Phase II trial of motexafin gadolinium (MGd, Xcytrin) and cranial radiation in newly diagnosed glioblasoma multiforme (GBM). Proc. Am. Soc. Ther. Radiol. Oncol. (2002) (Abstract 2108).
32. Rosenthal DI, Becerra CR, Toto RD, Carbone DP, Frenkel EP. Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin. Am. J. Clin. Oncol. 23(6), 593-598 (2000).
33. Ford JM, Seiferheld W, Mehta M, Phan S, Curran W. Comparison of survival of patients in the Phase I study of motexafin gadolinium (MGd) with radiation therapy (RT) for glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG RPA glioma database. Proc. Am. Soc. Clin. Oncol. 3 (2003) (Abstract 425).
34. De Stasio G, Casalbore P, Pallini R et al. Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. Cancer Res. 61(10), 4272-4277 (2001).
35. Hofmann B, Fischer CO, Lawaczeck R, Platzek J, Semmler W. Gadolinium neutron capture therapy (GdNCT) of melanoma cells and solid tumors with the magnetic resonance imaging contrast agent Gadobutrol. Invest. Radiol. 34(2), 126-133 (1999).